Drawing for DIRECTEDLUCK

USPTO serial 79316560

DIRECTEDLUCK

Reviewed by CopyMark Law Group

Reg. 6762956Status 700Registered
Filing date
Status date
Registration date
Jun 21, 2022
Examiner
MAHMOUDI, MARIAM AZIZ
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DIRECTEDLUCK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maryann E. Licciardi

Maryann E. Licciardi Cowan, Liebowitz & Latman, P.C.114 West 47th Street, 21st FloorNew York, NY 10036-1525UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Protein expression systems, namely, human proteins for life science and medical researchACTIVE—
005Biological preparations for pharmaceutical and veterinary purposes, in particular biological preparations developed from biological cells for the treatment of cancer, inflammatory disease and infectious disease; biological diagnostic preparations for medical and veterinary use; cells for medical use; viral vaccines; vaccine adjuvantsACTIVE—
040Custom manufacturing services of drugs; custom manufacture of pharmaceuticals; custom manufacture of proteins and vaccines and gene therapy with the aid of biological cells, including manufacture of biological active substancesACTIVE—
042Research and development in the fields of bacteriology, cellular engineering, cytology, antibodies, glycomics, chemistry, microorganisms, proteins, immunology, biological therapeutics, nutraceuticals and gene expression systems; scientific research and genome synthesis in the nature of genome amplification services for others; scientific and technological research services and research services in the fields of genetics, epigenetics and expression analysis; research and development in the field of biotechnology, namely, conducting protein expression; scientific and industrial research, in particular in the field of medicine, pharmacy, molecular biology, biotechnology and genetics; research and development of drugs, diagnostic and analytical preparations, therapy procedures and expression systems; research and development services relating to vaccines; scientific research in the field of genetics and genetic engineering; research in the field of gene therapyACTIVE—
044Medical services relating to the removal, treatment and processing of human cellsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 25, 2022FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 2, 2022FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 2, 2022FIMPFINAL DISPOSITION PROCESSED—
Sep 21, 2022FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 21, 2022NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jun 21, 2022R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 5, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 5, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 16, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 3, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 3, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Mar 3, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 3, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 3, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 25, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 25, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 25, 2022ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Feb 25, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 25, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 25, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 23, 2022RFNTREFUSAL PROCESSED BY IB—
Jan 4, 2022RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jan 4, 2022RFRRREFUSAL PROCESSED BY MPU—
Dec 11, 2021RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 10, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 7, 2021DOCKASSIGNED TO EXAMINER—
Aug 3, 2021MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 30, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 29, 2021REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance